Raul Rodriguez, Rigel CEO

Covid-19 roundup: Tiny sam­ple size leads FDA to turn down Rigel's EUA; Seat­tle biotech to co-de­vel­op mR­NA vac­cine in South Ko­rea

Four months af­ter Rigel an­nounced pos­si­ble Phase II re­sults for its Covid-19 treat­ment, the FDA has deemed the sam­ple size too …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.